Cargando…
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis
OBJECTIVE: Glucocorticoids (GC) withdrawal is part of the targets in current recommendations for SLE, but relapse is the most worrying issue. We aimed to investigate the predictors for flare in patients with SLE after GC withdrawal. METHODS: We systematically searched PubMed, EMBASE and Cochrane Lib...
Autores principales: | Ji, Lanlan, Xie, Wenhui, Fasano, Serena, Zhang, Zhuoli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744100/ https://www.ncbi.nlm.nih.gov/pubmed/34996857 http://dx.doi.org/10.1136/lupus-2021-000603 |
Ejemplares similares
-
Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study
por: Hao, Yanjie, et al.
Publicado: (2022) -
Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials
por: Xie, Wenhui, et al.
Publicado: (2021) -
Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus
por: Lokhandwala, Tasneem, et al.
Publicado: (2021) -
Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015
por: Hammond, Edward R, et al.
Publicado: (2021) -
Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study
por: Sada, Ken-ei, et al.
Publicado: (2022)